The role of intraperitoneal therapy in advanced ovarian cancer.
Intraperitoneal (i.p.) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both i.p. and intravenous (i.v.) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between i.p. and i.v. therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.
Hess
Lisa M
LM
Arizona Cancer Center Tucson, Arizona, USA.
Alberts
David S
DS
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003657:Decision Making; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D007263:Infusions, Parenteral / Q000009:adverse effects; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis